FindTrial
Sign In

Understanding Rituximab and its risk and benefits in treating patients with pemphigus.

Efficacy and safety of Rituximab infusion in pemphigus patients: A retrospective study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089549
Enrollment
25
Registered
2025-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L100- Pemphigus vulgaris

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Dr Harshini S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All pemphigus patients (fresh, relapse, and recalcitrant cases) with diagnosis confirmed by typical clinical presentation, direct immunofluorescence and biopsy who had received rituximab infusion 2. Patients with proper clinical records available. 3. Uninterrupted clinical follow-up of at least 12 months since the first rituximab treatment

Exclusion criteria

Exclusion criteria: Patients with missed data and lost to follow up

Design outcomes

Primary

MeasureTime frame
Pemphigus Area and Activity Score (PAAS)Timepoint: Baseline, 4 weeks and 8 weeks—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Harshini S

Hassan Institute of Medical Sciences

drsureshhsn@gmail.com9480303929

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026